drugset / Trial / NCT00033358

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

NCT00033358

Phase 2 Completed 52 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupOpen-labelPrevention

Summary

Randomized phase II trial to compare two different hormone therapy regimens in preventing endometrial cancer in women who have a genetic risk for hereditary nonpolyposis colon cancer. Hormone therapy may prevent the development of endometrial cancer in women with a genetic risk for hereditary nonpolyposis colon cancer. It is not yet known which hormone therapy regimen is more effective in preventing endometrial cancer.

Timeline

Start
2002-02
Primary completion
2007-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Norgestrel Unknown Oral
Subject ethinyl estradiol Small molecule Oral
Subject medroxyprogesterone acetate Other / unclassified Intramuscular

Indications